Videos

The first infant has been screened in the THRIVE trial evaluating the VIASKIN Peanut Patch as an early intervention for peanut allergy.

THRIVE has begun screening infants aged 6 to 12 months to evaluate whether early treatment with the VIASKIN Peanut Patch can alter peanut allergy.

An expert outlines communication and shared decision-making strategies that support adherence and trust, and describes emerging patient-centered outcomes that are reshaping future care paradigms in pediatric functional constipation and IBS-C.

RSV prevention shifts: maternal vaccines and nirsevimab protect infants when timed right, cutting hospitalizations and closing care gaps.

This episode bridges the gap between clinical trial data and everyday practice, focusing on how pediatricians can systematically ensure no eligible infant falls through the cracks.

A protective lithium coin-cell battery may reduce severe injuries, but experts say prevention and emergency management remain essential.

A new study found a protective lithium coin-cell battery reduced tissue injury, but experts say current emergency treatment should remain unchanged.

Explore the heterogeneity of pediatric functional constipation and IBS-C, the limitations of one-size-fits-all algorithms, and the importance of integrating dietary, behavioral, and psychosocial interventions alongside pharmacologic therapy.

In this episode, Dr. Simões reviews the post-licensure landscape, highlighting data from real-world effectiveness studies now emerging from multiple countries. Initial real-world data for one monoclonal antibody came from the UK and France, including pragmatic trial evidence. Argentina provided complementary data on maternal immunization, having implemented it as an exclusive strategy — while the UK used monoclonal antibody prophylaxis exclusively and France deployed both approaches, offering a natural comparison. A notable French population-based study published in JAMA found a statistically significant difference in effectiveness between the two strategies; however, Dr. Simões cautions that the overlapping 95% confidence intervals suggest the clinical difference may not be meaningful. Importantly, real-world effectiveness broadly mirrors the results seen in randomized controlled trials — a reassuring finding that validates these interventions at scale. Dr. Simões highlights that real-world studies are beginning to capture outcomes not measured in trials, including effects on ICU admissions, otitis media, and all-cause respiratory hospitalizations. For second-season protection, early data with nirsevimab suggests continued benefit, though the full picture is still emerging. Evidence for clesrovimab's second-season efficacy has been presented at scientific meetings and reviewed by the FDA but has not yet received formal approval in the U.S. for this indication. The panel agrees that as additional seasons accumulate data, the understanding of sustained protection will sharpen considerably. In the next episode, "RSV Prevention in Practice: Eliminating Gaps in Immunization Coverage," Dr. Creech and Dr. Tan review the common gaps in RSV prophylaxis delivery and how pediatric practices can build systems to ensure every eligible infant is protected.

New RSV shots and monoclonals cut infant hospitalizations up to 85%, with strong real‑world safety—learn what efficacy vs effectiveness really means.

A Nemours program trained pediatric residents to conduct autism evaluations, improving confidence and helping families access care sooner.

A multicenter trial found enhanced recovery protocols improved outcomes in pediatric GI surgery when implemented with high adherence.

An expert reviews the pediatric IBS-C label expansion for linaclotide, discusses how it addresses historical evidence gaps, and outlines practical considerations for patient selection, counseling, and monitoring.

Maternal RSV vaccination and monoclonal antibodies protect infants differently, from breastfeeding IgA transfer to long-acting antibodies—plus what trial data reveals.

Compare maternal RSV vaccination vs long-acting antibodies: breast milk IgA, half-life tradeoffs, and little herd protection.

An expert underscores the importance of early expectation setting around chronicity, symptom variability, and realistic treatment goals for children with functional constipation or IBS-C.

Why viral testing matters in infants: RSV, flu and more guide prognosis, parent counseling, and prevention—despite cost and reimbursement hurdles.

Learn how maternal vaccination and new RSV antibodies protect infants—timing, dosing, and seasonal guidance to prevent hospitalizations.

A new Surgeon General advisory links excessive screen use to developmental, mental, physical, and academic risks in children and adolescents.

Learn how Rome V criteria, predominant symptom drivers, and a positive diagnostic framework help clinicians distinguish functional constipation from pediatric IBS-C and move away from a diagnosis-of-exclusion mindset.

Mental health diagnoses are appearing in more pediatric primary care visits, with anxiety showing the largest increase over the past decade.

Why skipping viral tests harms care: targeted RSV, flu, and COVID diagnosis guides prognosis, parent counseling, and prevention in infants.

Learn why RSV hits older adults hardest: cumulative comorbidities, global seasonality shifts, and how timing shapes vaccines and prophylaxis.

Colleen Cotton, MD, outlines a simple screening approach that may help pediatricians identify hidradenitis suppurativa earlier.

Colleen Cotton, MD, explains how early referral, flare management, and comorbidity screening may help improve outcomes for children with hidradenitis suppurativa.

Jamie Wood, MD, explains how the FDA approval of Afrezza for children aged 6 years and older adds a new mealtime insulin option, offering flexibility beyond injections and pumps.

Early referral, school accommodations, and patient education may help improve quality of life for children with hidradenitis suppurativa.

Julie Khlevner, MD, discusses the clinical impact of FDA approval of linaclotide for children aged 2 to 5 years with functional constipation.

Colleen Cotton, MD, FAAD, outlines key skin findings that may help pediatricians distinguish hidradenitis suppurativa from other conditions.

Early diagnosis of hidradenitis suppurativa in adolescents may help prevent scarring and improve treatment response, according to Colleen Cotton, MD, FAAD.